Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07538570 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Pain Treatment After Total Knee Arthroplasty
A Phase 4 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT07538570 is a Phase 4 study that is actively recruiting participants, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 60 participants.
The verdict
NCT07538570, a Phase 4 study, is actively recruiting participants, sponsored by Vertex Pharmaceuticals Incorporated.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of the study is to characterize opioid use after total knee arthroplasty (TKA).
Interventions
- DRUG Placebo
- DRUG Suzetrigine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-04-24 |
| Est. Completion | 2027-01-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07538570
The ClinicalTrials.gov registry entry for NCT07538570 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07538570 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07538570 about?
NCT07538570 is a clinical study titled "Evaluation of Pain Treatment After Total Knee Arthroplasty". The purpose of the study is to characterize opioid use after total knee arthroplasty (TKA).
What is the current status of trial NCT07538570?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2026-04-24. Estimated completion is 2027-01-30.
What interventions are being tested in trial NCT07538570?
The interventions under investigation include: Placebo (DRUG), Suzetrigine (DRUG).
Who is sponsoring clinical trial NCT07538570?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.